APA

Braud A. C., Mathoulin Portier M. P., Bardou V. J., Bertucci F., Gravis G., Camerlo J., Begue M., Houvenaeghel G., Maraninchi D., Jacquemier J. & Viens P. (20030711). Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation. : Bone marrow transplantation.

Chicago

Braud A C, Mathoulin Portier M P, Bardou V J, Bertucci F, Gravis G, Camerlo J, Begue M, Houvenaeghel G, Maraninchi D, Jacquemier J and Viens P. 20030711. Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation. : Bone marrow transplantation.

Harvard

Braud A. C., Mathoulin Portier M. P., Bardou V. J., Bertucci F., Gravis G., Camerlo J., Begue M., Houvenaeghel G., Maraninchi D., Jacquemier J. and Viens P. (20030711). Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation. : Bone marrow transplantation.

MLA

Braud A C, Mathoulin Portier M P, Bardou V J, Bertucci F, Gravis G, Camerlo J, Begue M, Houvenaeghel G, Maraninchi D, Jacquemier J and Viens P. Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation. : Bone marrow transplantation. 20030711.